Puretech announces new therapeutic candidate, lyt-310, an oral form of cannabidiol (cbd) leveraging puretech's glyph™ platform

Boston--( business wire )--puretech health plc (nasdaq: prtc, lse: prtc) ("puretech" or the "company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced the nomination of a new therapeutic candidate, lyt-310, which is an oral cannabidiol (cbd) prodrug and the second therapeutic candidate developed from puretech's glyph™ platform to be advanced toward the clinic. clinical studies of lyt-310 are expected to begin in q4 of 2023.
PRTC Ratings Summary
PRTC Quant Ranking